Preimplantation Genetic Testing Market

The global preimplantation genetic testing market is expected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during the forecast period. Factors such as the declining fertility rate worldwide, rising maternal age and rising number of fertility clinics worldwide are expected to drive the demand for preimplantation genetic testing market. According to the World Health Organization (WHO), in 2020, approximately 8 million couples and 186 million individuals lived with infertility.

The preimplantation genetic testing market is highly consolidated and is dominated by various players. The major players operating in this market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), and The Cooper Companies, Inc. (US). These include a range of initiatives such as introducing new products, establishing contracts and partnerships, pursuing mergers and acquisitions, and engaging in new product development endeavors. These actions aim to enhance their position in the market for preimplantation genetic testing.

To know about the assumptions considered for the study download the pdf brochure

Illumina, Inc.

In 2022, Illumina, Inc. (U.S.) held the leading position in the global preimplantation genetic testing market. The company has been focusing on the strategy of agreements, partnerships, and product launches to maintain its position in the market. The company’s preimplantation genetic testing portfolio includes VeriSeq PGS, MiSeq System, and BlueFuse Multi Analysis Software in the market, which enabled it to garner a high share. The company has a strong global presence with more than 54% of its revenue generated from the Americas and around 27% from the European region.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific held the second position in the market due to its extensive portfolio of sequencing instruments & consumables. Thermo Fisher Scientific aims to expand its product portfolio by introducing innovative products in the filed next-generation sequencing. The company has a a well-established distribution channel which leads to Thermo Fisher Scientific holding a signoficant share in the preimplantation genetic testing market in 2022.

Agilent Technologies, Inc.

In 2022, Agilent Technologies, Inc. was the third-largest player. The company employs multiple distribution channels and a direct sales team in around 30 countries to sell its products directly to hospitals, testing laboratories and medical centers. Its direct sales team enables the firm to focus on its products. The company has a robust portfolio of preimplantation genetic testing in its diagnostics and genomics segments.

Related Reports:

Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]